Cargando…
Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats
Ethionamide (ETH), a second‐line drug for multidrug‐resistant tuberculosis, is known to cause hepatic steatosis in rats and humans. To investigate predictive biomarkers for ETH‐induced steatosis, we performed lipidomics analysis using plasma and liver samples collected from rats treated orally with...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546090/ https://www.ncbi.nlm.nih.gov/pubmed/35315511 http://dx.doi.org/10.1002/jat.4324 |
_version_ | 1784804964786241536 |
---|---|
author | Muta, Kyotaka Saito, Kosuke Kemmochi, Yusuke Masuyama, Taku Kobayashi, Akio Saito, Yoshiro Sugai, Shoichiro |
author_facet | Muta, Kyotaka Saito, Kosuke Kemmochi, Yusuke Masuyama, Taku Kobayashi, Akio Saito, Yoshiro Sugai, Shoichiro |
author_sort | Muta, Kyotaka |
collection | PubMed |
description | Ethionamide (ETH), a second‐line drug for multidrug‐resistant tuberculosis, is known to cause hepatic steatosis in rats and humans. To investigate predictive biomarkers for ETH‐induced steatosis, we performed lipidomics analysis using plasma and liver samples collected from rats treated orally with ETH at 30 and 100 mg/kg for 14 days. The ETH‐treated rats developed hepatic steatosis with Oil Red O staining‐positive vacuolation in the centrilobular hepatocytes accompanied by increased hepatic contents of triglycerides (TG) and decreased plasma TG and total cholesterol levels. A multivariate analysis for lipid profiles revealed differences in each of the 35 lipid species in the plasma and liver between the control and the ETH‐treated rats. Of those lipids, phosphatidylcholine (PC) (18:0/20:4) decreased dose‐dependently in both the plasma and liver. Moreover, serum TG‐rich very low‐density lipoprotein (VLDL) levels, especially the large particle fraction of VLDL composed of PC containing arachidonic acid (20:4) involved in hepatic secretion of TG, were decreased dose‐dependently. In conclusion, the decreased PC (18:0/20:4) in the liver, possibly leading to suppression of hepatic TG secretion, was considered to be involved in the pathogenesis of the ETH‐induced hepatic steatosis. Therefore, plasma PC (18:0/20:4) levels are proposed as mechanism‐related biomarkers for ETH‐induced hepatic steatosis. |
format | Online Article Text |
id | pubmed-9546090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95460902022-10-14 Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats Muta, Kyotaka Saito, Kosuke Kemmochi, Yusuke Masuyama, Taku Kobayashi, Akio Saito, Yoshiro Sugai, Shoichiro J Appl Toxicol Research Articles Ethionamide (ETH), a second‐line drug for multidrug‐resistant tuberculosis, is known to cause hepatic steatosis in rats and humans. To investigate predictive biomarkers for ETH‐induced steatosis, we performed lipidomics analysis using plasma and liver samples collected from rats treated orally with ETH at 30 and 100 mg/kg for 14 days. The ETH‐treated rats developed hepatic steatosis with Oil Red O staining‐positive vacuolation in the centrilobular hepatocytes accompanied by increased hepatic contents of triglycerides (TG) and decreased plasma TG and total cholesterol levels. A multivariate analysis for lipid profiles revealed differences in each of the 35 lipid species in the plasma and liver between the control and the ETH‐treated rats. Of those lipids, phosphatidylcholine (PC) (18:0/20:4) decreased dose‐dependently in both the plasma and liver. Moreover, serum TG‐rich very low‐density lipoprotein (VLDL) levels, especially the large particle fraction of VLDL composed of PC containing arachidonic acid (20:4) involved in hepatic secretion of TG, were decreased dose‐dependently. In conclusion, the decreased PC (18:0/20:4) in the liver, possibly leading to suppression of hepatic TG secretion, was considered to be involved in the pathogenesis of the ETH‐induced hepatic steatosis. Therefore, plasma PC (18:0/20:4) levels are proposed as mechanism‐related biomarkers for ETH‐induced hepatic steatosis. John Wiley and Sons Inc. 2022-03-29 2022-09 /pmc/articles/PMC9546090/ /pubmed/35315511 http://dx.doi.org/10.1002/jat.4324 Text en © 2022 The Authors. Journal of Applied Toxicology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Muta, Kyotaka Saito, Kosuke Kemmochi, Yusuke Masuyama, Taku Kobayashi, Akio Saito, Yoshiro Sugai, Shoichiro Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats |
title | Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats |
title_full | Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats |
title_fullStr | Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats |
title_full_unstemmed | Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats |
title_short | Phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats |
title_sort | phosphatidylcholine (18:0/20:4), a potential biomarker to predict ethionamide‐induced hepatic steatosis in rats |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546090/ https://www.ncbi.nlm.nih.gov/pubmed/35315511 http://dx.doi.org/10.1002/jat.4324 |
work_keys_str_mv | AT mutakyotaka phosphatidylcholine180204apotentialbiomarkertopredictethionamideinducedhepaticsteatosisinrats AT saitokosuke phosphatidylcholine180204apotentialbiomarkertopredictethionamideinducedhepaticsteatosisinrats AT kemmochiyusuke phosphatidylcholine180204apotentialbiomarkertopredictethionamideinducedhepaticsteatosisinrats AT masuyamataku phosphatidylcholine180204apotentialbiomarkertopredictethionamideinducedhepaticsteatosisinrats AT kobayashiakio phosphatidylcholine180204apotentialbiomarkertopredictethionamideinducedhepaticsteatosisinrats AT saitoyoshiro phosphatidylcholine180204apotentialbiomarkertopredictethionamideinducedhepaticsteatosisinrats AT sugaishoichiro phosphatidylcholine180204apotentialbiomarkertopredictethionamideinducedhepaticsteatosisinrats |